CoChat

2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis

Open access
Humphrey, Mary Beth, Russell, Linda, Danila, Maria I., Fink, Howard A., Guyatt, Gordon, Cannon, Michael, Caplan, Liron, Gore, Sara, Grossman, Jennifer, Hansen, Karen E., Lane, Nancy E., Ma, Nina S., Magrey, Marina, McAlindon, Tim, Robinson, Angela Byun, Saha, Sumona, Womack, Charles, Abdulhadi, Basma, Charles, Julia F., Cheah, Jonathan T. L., Chou, Sharon, Goyal, Itivrita, Haseltine, Katherine, Jackson, Lesley, Mirza, Reza, Moledina, Iram, Punni, Emma, Rinden, Tim, Turgunbaev, Marat, Wysham, Katherine, Turner, Amy S., Uhl, Stacey · 2023 · Arthritis & Rheumatology
Cited by 197

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Objective: The objective is to update recommendations for prevention and treatment of glucocorticoid‐induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic conditions receiving >3 months treatment with glucocorticoids (GCs) ≥2.5 mg daily. Methods: An updated systematic literature review was performed for clinical questions on nonpharmacologic, pharmacologic treatments, discontinuation of medications, and sequential therapy. Grading of Recommendations Assessment, Development and Evaluation approach was used to rate the certainty of evidence. A Voting Panel achieved ≥70% consensus on the direction (for or against) and strength (strong or conditional) of recommendations. Results: For adults beginning or continuing >3 months of GC treatment, we strongly recommend as soon as possible after initiation of GCs, initial assessment of fracture risks with clinical fracture assessment, bone mineral density with vertebral fracture assessment or spinal x‐ray, and Fracture Risk Assessment Tool if ≥40 years old. For adults at medium, high, or very high fracture risk, we strongly recommend pharmacologic treatment. Choice of oral or intravenous bisphosphonates, denosumab, or parathyroid hormone analogs should be made by shared decision‐making. Anabolic agents are conditionally recommended as initial therapy for those with high and very high fracture risk. Recommendations are made for special populations, including children, people with organ transplants, people who may become pregnant, and people receiving very high‐dose GC treatment. New recommendations for both discontinuation of osteoporosis therapy and sequential therapies are included. Conclusion: This guideline provides direction for clinicians and patients making treatment decisions for management of GIOP. These recommendations should not be used to limit or deny access to therapies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/art.42646

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

See all 197

Metadata

Authors
Humphrey, M. B., Russell, L., Danila, M. I., Fink, H. A., Guyatt, G., Cannon, M., Caplan, L., Gore, S., Grossman, J., Hansen, K. E., Lane, N. E., Ma, N. S., Magrey, M., McAlindon, T., Robinson, A. B., Saha, S., Womack, C., Abdulhadi, B., Charles, J. F., Cheah, J. T. L., Chou, S., Goyal, I., Haseltine, K., Jackson, L., Mirza, R., Moledina, I., Punni, E., Rinden, T., Turgunbaev, M., Wysham, K., Turner, A. S., & Uhl, S.
Venue
Arthritis & Rheumatology
Publisher
Wiley
Published
2023-10-16
Volume
75
Issue
12
Pages
2088-2102
ISSN
  • 2326-5191 (ISSN-L)
  • 2326-5205
OpenAlex
W4387691765
Cited by
197
References
9
FWCI
51.11
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. https://app.cochat.ai/papers/10.1002/art.42646
The paper
Humphrey, M. B., Russell, L., Danila, M. I., Fink, H. A., Guyatt, G., Cannon, M., Caplan, L., Gore, S., Grossman, J., Hansen, K. E., Lane, N. E., Ma, N. S., Magrey, M., McAlindon, T., Robinson, A. B., Saha, S., Womack, C., Abdulhadi, B., Charles, J. F., . . . Uhl, S. (2023). 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid‐Induced Osteoporosis. Arthritis & Rheumatology. https://doi.org/10.1002/art.42646

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.